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Systematic review of amodiaquine treatment in uncomplicated 
malaria 
P Olliaro, C Nevill, J LeBras, &’ngwald, P Mussano, P Garner, P Brasseur 
Summary 
Background Opinion and policy over the use of amodiaquine 
for treating malaria vary. Amodiaquine is more palatable 
than chloroquine and may be more effective but serious 
adverse events have been reported in travellers taking it as 
prophylaxis. It is not recommended as first-line treatment. 
In the light of the global debate over the use of this drug, 
we conducted a systematic review of the effectiveness and 
tolerability of amodiaquine in the treatment of 
uncomplicated falciparum malaria. 
Methods This is a systematic review of published and 
unpublished randomised or pseudorandomised trials of 
amodiaquine. Observational reports were also 
systematically identified and reviewed to  access evidence 
of serious adverse events. 
Findings 40 trials met the inclusion criteria. Symptomatic 
patients were enrolled in 2 4  studies in comparisons of 
amodiaquine (n=1071) wi th chloroquine (n=1097). 
Amodiaquine was significantly more effective than 
chloroquine, with odds ratios and 99% confidence intervals 
(OR [99% CI]) of 4.29 (3.30-5.58) on day 7 and 6.00 
(3-97-9.06) on day 14. Time to  parasite clearance was 
significantly shorter with amodiaquine and fever clearance 
times were marginally faster. Eight studies compared 
amodiaquine with chloroquine in asymptomatic 
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parasitaemia, with effects on parasitological outcomes 
similar to those for symptomatic malaria. A t  twelve sites, 
692 amodiaquine and 679 sulfadoxine/pyrimethamine 
(S/P) recipients were enrolled. The two drugs did not differ 
significantly on day 7 (OR 0-74 [0.48-1-15]) but the odds 
ratios favoured S/P on day 14 (OR 0.51 [0.28-0.93]) and 
on day 28 (OR 0.30 [0.16-0-55]). The t ime t o  
parasitological clearance was similar in the two groups; 
fever clearance times were significantly shorter with 
amodiaquine. Tolerability was assessed for both 
comparative and non-comparative trials. The rates of 
adverse events in controlled trials were 10.7%, 8.8%, and 
14.3% with amodiaquine, chloroquine, and S/P, 
respectively. No life-threatening adverse events and no 
significant shifts in laboratory indices were reported. 
interpretation This systematic review of published and 
unpublished trials supports the use of amodiaquine in the 
treatment of uncomplicated malaria. However, there is 
partial cross-resistance between chloroquine and 
amodiaquine, and monitoring of the effectiveness of this 
drug and surveillance for evidence of toxici ty must 
continue. 
Lancet 1996; 348: 1196-201 
See Commentary page 1184 
Introduction 
Amodiaquine is a 4-aminoquinoline used widely in the 
past to treat and prevent malaria. In the mid-I980s, 
reports of fatal adverse drug reactions (ADRs) were 
described in travellers using amodiaquine as prophylaxis.iJ 
As a consequence one manufacturer (Parke-Davis) 
modified the labelling and withdrew prophylaxis as an 
indication, and in 1990 the World Health Organization 
(WHO) stopped using this drug in malaria control 
pr~grammes.~ WHO’S 19th Expert Committee on Malaria 
modified this in 1993 to say that “amodiaquine could be 
used for treatment if the risk of infection outweighs the 
potential for [adverse drug reactions]”, but still do not 
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recommend amodiaquine as first-line treatment.4 These 
statements have caused considerable confusion; several 
countries have banned amodiaquine whilst others have 
continued to use it as second or first line treatment for 
uncomplicated malaria. 
The drug may have advantages over chloroquine: it may 
retain its efficacy in some areas of Africa where there is 
chloroquine resistance; it is more palatable and therefore 
easier to administer to children; and itching may be less 
with amodiaquine treatment. Most reports of toxicity have 
been with prophylactic rather than therapeutic use. It has 
also been suggested that amodiaquine may be a less toxic 
alternative to pyrimethaminelsulfadoxine (SIP) in HIV 
infected patients in sub-Saharan Africa.’ Moreover, 
amodiaquine is widely available and some countries have 
local facilities to produce it; it is also the cheapest 
antimalarial drug after chloroquine. The global debate over 
the use of this drug prompted us to do a systematic review 
of the effectiveness and tolerability of amodiaquine in the 
treatment of uncomplicated falciparum malaria. 
Materials and methods 
Inclusion criteria and search strategy 
Inclusion criteria were predetermined in terms of participants 
(adults or children with uncomplicated falciparum malaria or 
asymptomatic Plusinodiuni fulciparunt parasitaemia); of 
interventions (treatment with amodiaquine in randomised and 
altemate allocation comparisons with other treatment regimens); 
and of outcomes (parasitological conversion, parasite clearance 
time, fever clearance time). Any reported tolerability indices or 
adverse reactions were also extracted. 
The search strategy involved an electronic search on 
MEDJ..DE, a search of the Cochrane Tropical Diseases Group 
trials register (which covers 25 journals, three in French): and 
seeking unpublished and raw data from researchers and drug 
companies. 
Efficacy 
All identified mals were entered into a trial register. The inclusion 
criteria were then applied to mals separately by three people, and 
trials qualifying for analyses were retained. The quality of each 
included trial was assessed with respect to the adequacy of 
concealment, allocation procedures, blinding, and follow-up 
quality, using the standard protocol of the Cochrane Tropical 
Diseases Group.6 Wherever possible, original data were obtained 
and analyses of individual patient data using the prespecified 
outcome measures were done. To minimise selection bias and the 
effect of patient attrition, the proportion of parasitological success 
was calculated from the total number of patients reportedly 
“evaluable” on day 7, 14, and 28. “Success” was a patient who 
was assessed and had a negative smear; “failures” were patients 
who were assessed and had a positive smear or were lost to follow- 
up. The odds ratio and 95% confidence intervals (OR, 95% CI) 
were calculated for individual studies meeting the inclusion criteria 
and these are that CIS used in individual lines in figures 1 and 2.  
The Cochrane Collaboration prefers 99% CIS and these are the 
intervals used for subtotal ORs in figures 1 and 2 and in the rest of 
this article. Pooled estimates of effectiveness were calculated from 
a weighted average, weight being based on the inverse of the 
variance.’ 
Time to parasitological clearance was calculated for individual 
studies and on the pooled data using the Kaplan-Meier procedure. 
Depending on the available time-points for analysis, two pools of 
data were created for trials using chloroquine as the comparator 
drug: pool A with six time-points (days O, 1, 2, 3, 5, and 7) and 
pool B with assessments on days O, 1, 2, and 7. For trials of 
amodiaquine compared with SIP, five data points (days O, 1, 2, 3, 
and 7) were used. The log-rank test was used to compare the 
results of the amodiaquine and the comparator arm. In this 
OR (95% CI) Comparison Day Studies success/no treated (%) 
Amodiaquine Comparator --- 
Chloroquine 7 24 890/1071(834.) 614/1097 (56.0) 4.29 (3.30-5.58) 
14 9 390/444 (87.8) 250/447 (55.9) 6.00 (3.97-9.06) 
s/p 7 12 588/692 (85.0) 598/679 (88.1) 0.74 (0.48-1.15) 
14 6 267/325 (82.2) 303/343 (89.8) 0.51 (0.28-0.93) 
28 4 134/212 (63.2) 154/180 (85.6) 0.30 (0.16-065) 
--- 
*Odds ratio for amodiaquinexomparator. 
Table 1: Parasitological success  of amodiaquine compared 
with chloroquine or with S/P in symptomatic malaria 
analysis, in which all patients with a baseline positive smear were 
considered, achievement of parasite clearance was preferred to 
parasite clearance time as reported in the published papers 
because time to clearance is restricted to those patients who were, 
eventually, cleared of parasites. Weighted mean differences with 
lower and upper confidence limits were used for analysing fever 
clearance time (FCT).8 
Tolerability 
An additional search was conducted to identify studies without 
control groups reporting adverse reactions. Data from trials 
included in the effectiveness review, as well as trials excluded 
because they did not meet inclusion criteria, were scrutinised for 
safety data. Only trials which specifically mentioned tolerability 
measures were considered, and all outcomes that could be 
interpreted as reflecting tolerability were summarised. Reports of 
adverse events were also sought from the WHO Collaborating 
Centre for Intemational Drug Monitoring and from the Parke- 
Davis database. 
Results 
72 studies between 1983 and 1995 were identified, of 
which 40 (37 from Africa) met the inclusion criteria. 17 of 
the 40 were published, 5 were unpublished, and 18 were in 
the form of raw data (these studies include published 
articles for which individual patient data were made 
available by the trialist and Parke-Davis). Individual 
patient data accounted for about one-third of total 
amodiaquine patients in the comparison with chloroquine 
and more than half of those comparing amodiaquine with 
SIP. Amodiaquine was administered at doses ranging from 
15.6 to 35 mg/kg over, three days. Full details of location, 
participants, methods, and drug regimens of the 40 trials 
are available on the Cochrane database.** 
Trial quality was assessed, starting with allocation 
c~ncealment .~ Of the 40 studies, allocation was adequately 
concealed in three, and either not clearly described or 
unconcealed in 37. Except for one trial in the Philippines 
and one in China, no study was blinded. Six trials specified 
the method of generating the sequence, 22 mentioned 
randomisation but were not specific about the method, and 
12 used methods that appeared to be unbiased. Nine 
studies used an intention-to-treat analysis with few losses 
to follow-up; eight trials report exclusions with levels of less 
than 10%; in the remaining 23, there was either no 
reporting of exclusions or exclusions were greater than 
10%. Quality of number generation and analysis was better 
in the three trials with adequate concealment of allocation. 
Eight trials scored low on all three indices of quality. 
Diagnostic procedures varied with centres, although in 
most of them patients were admitted on the basis of thick 
and thin blood film results. No quality control of slide 
reading was mentioned in any of the studies. In 11 studies 
in Kenya, 10% of slides were systematically checked by a 
distant observer blind to the original results. 
*A list of the 40 studies is obtainable from The Lancet 
3 
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Comparison: 
Outcome: Parasitologic success 
Study Expt nlN Ctrl n lN Weight 
amodiaquine vs chloroquine in symptomatic patients 
Peto OR (95%CI)! 
~ 
day 7 
Brazil 1983-84 
Cameroun-Kumba 92 
Cameroun-South 88 
CamerounBangangt92 
CamerounYaounde 92 
Congo 92 
Congo P-Noire 86 
EquatorialGuinea91 
Gambia 94 
Ivory Coast 93 
Kenya 1989 
Kenya-Entosopia 91 
Kenya-Kilifi 1993 
Kenya-Mafindi 1984 
Kenya-Migori 1990 
Kenya-Ortum 1991 
Kenya-Turlani 1991 
Kenya-Turiani 1992 
Kenya-West 1987 
Madagascar 83/84 
Madagascar 85/86 
Nigeria-Ibadan 84 
Nigeria-Ibadan 90 
Philippines 84/85 
Subtotal (99%Cl) 
Chi-square 203.40 (df=22) 
day 14 
EquatorialGuinea91 
Kenya 1989 
Kenya-Kilifi 1993 
Kenya-Malindi 1984 
Kenya-Turiani 1992 
Madagascar 83/84 
Madagascar 85186 
Nigeria-Ibadan 90 
Philippines 84/85 
Subtotal (99%Cl) 
Chi-square 125.14 (df=8) 
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Figure 1: Trials comparing amodiaquine and chloroquine in symptomatic patients 
Parasitological success (n) at day 7 and day 14 in total patients treated (N). 
Amodiaquine versus chloroquine 
Symptomatic uncomplicated falciparum malaria. 107 1 
patients received amodiaquine and 1097 chloroquine with 
studies at 24 slides, of which 22 were from Africa 
(accounting for 96% of the amodiaquine patients; 39% 
from Kenya, 16% from Cameroon). In this analysis 
patients with a positive smear or no data on day 7 were 
deemed failures. Amodiaquine was significantly more 
effective than chloroquine on day 7 (parasitological 
success rates 83% and 56%, respectively); the OR was 
4.29 (99% CI 3.30-5.58). Few studies followed patients 
up to day 14 (444 amodiaquine, 447 chloroquine); 
nonetheless the parasitological success rates remained 
significantly different at 88% and 56%, respectively (OR 
6.00 [3-97-9*06]) (table 1, figure 1). Because patients 
were not available for follow-up at day 14 were simply 
excluded, ORs for day 7 and day 14 should not be directly 
compared. Time to parasite clearance (day O through 7) 
was significantly shorter with amodiaquine than 
chloroquine whether the analysis used six or four data 
points (log-rank p=0.0025 and 0.0001, respectively) 
(table 2). Fever clearance (FCT) tended to be more rapid 
with amodiaquine (n=242) compared with chloroquine 
(n=230) in the four studies where it as reported, but the 
difference was not significant (weighted mean difference 
146 min [99% CI -49 to +371). 
Asymptomatic malaria parasitaemia. 488 amodiaquine 
recipients were compared with 482 chloroquine controls 
in eight studies. The success rate on  day 7 was 
significantly higher for amodiaquine (91% vs 76%; 
ORz3.32 [99% CI 2*07-5*32]). 
1198 Vol 348 November 2,1996 
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Comparison: 
Outcome: Parasitologic success 
Study Expt n/N Ctrl n/N Weight Peto OR (95%CI) 
amodiaquine vs pyrimethaminelsulfadoxine in symptomatic patients 
day 7 
Brazil 1983-84 
China 1986 
EquatorialGuinea91 
Gambia 94 
Kenya-Entosopia 94 
Kenya-Malla 1994 
Kenya-Mombasa 90 
Kenya-Nangina 1993 
Kenya-Sololo 1993 
Kenya-Taveta 1994 
Malawi 1985 
Nigeria-Ibadan 90 
Subtotal (99%CI) 
Chi-square 3.13 (df=9) 
day 14 
EquatorialGuinea91 
Kenya-Entosopia 94 
Kenya-Malla 1994 
Kenya-Mombasa 90 
Kenya-Taveta 1994 
Malawi 1985 
Nigeria-Ibadan 90 
Subtotal (99%Cl) 
Chi-square 8.35 (df=4) 
day 21-28 
China 1986 
Gambia 94 
Kenya-Mombasa 90 
Malawi 1985 
Subtotal (99%Cl) 
Chi-square 26.07 (df=3) 
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Figure 2: Trials comparing amodiaquine and pyrimethamine/sulfadoxine in symptomatic patients 
Parasitological success (n) at  day 7, day 14, or day 21-28 in total patients treated (N). 
Amodiaquine versus S/P 
Symptomatic uncomplicated falc iparum malaria. Studies 
were done at 12 sites (10 from Africa) with 692 
amodiaquine and 679 SIP recipients. Four studies also 
had a chloroquine arm. On day 7 the success rates were 
85% with amodiaquine and 88% with S/P (OR=O-74 
[99% CI  0-48-1.151). 325 and 343 patients were 
evaluable at day 14, respectively, and 212 and 180 on day 
28. The OR became significant by day 14 in favour of S/P 
(success rates 82.2% and 894%; OR=O.51 [99% CI 
0*28-0.93]), and more strongly so by day 28 (63.2% and 
85.6%; ORzO.30 [0.16-0*55]) (table 1, figure 2). The 
Data points Treatment Total Success (%) Censored (%) Logrank p 
0,1,2,3,5,7 ADQ 108 99f91.61 9 (8.3) 0.0025 
0,1,2,7 ADP 519 478 (92.1) 41 (7.9) 0.0001 
01,2,3,7 ADQ 424 385f90.8) 39f9.2) 0.27 
-- (days) 
CLQ 109 78 (71.6) 31  (28.4) 
CLQ 509 307 (60.3) 202 (39.7) 
S/P 451 401 (88.9) 50 (11.1) 
Table 2: Time to parasite clearance 
0.37 [0.14,0.98] 
0.61 [0.08,4.44] 
1.98 [0.20,19.57] 
0.87 [0.42,1.81] 
0.84 [0.42,1.70] 
2.19 [0.91,5.27] 
0.14 [0.05,0.41] 
3.41 [0.58,20.04] 
0.61 [0.24,1.54] 
0.14 [0.01,2.33] 
0.74 [0.48,1.15] 
1 .o0 [0.00,0.00] 
1 .o0 [0.00,0.00] 
0.17 [0.04,0.62] 
0.43 [0.21,0.88] 
2.51 [0.95,6.63] 
0.56 [0.16,1.99] 
0.1 1 [0.03,0.46] 
0.51 [0.28,0.93] 
1 .o0 [0.00,0.00] 
1 .o0 [0.00,0.00] 
0.28 [0.09,0.85] 
0.44 [0.25,0.80] 
0.12 [0.02,0.90] 
0.09 [0.03,0.30] 
0.30 [0.16,0.55] 
time to parasitological clearance (day O to 7) was similar in 
the two groups (log-rank p=0.27, table 2). FCTs 
(reported in five trials on 290 and 281 amodiaquine and 
SIP patients, respectively) were shorter with amodiaquine, 
the weighted mean difference being 1 5 5  h (99% CI 
, 
-11.3 to -19.8 h). 
Asymptomatic malaria parasitaemia. Two studies 
included in the eight studies of amodiaquine and 
chloroquine in asymptomatic P falciparunz-infected 
patients also had a S E  arm. Those two enrolled 143 
amodiaquine and 122 S/P recipients, with success rates on 
day 7 of 93% and 99%, respectively. 
Comparison Studies Patients with adverse events/ OR (95% CI) 
no treated (%) 
Amodiaquine* Comparator - 
Chloroquine 8 33/143 (8) 36/411 (84) 0.85 (0.43-1.67) 
s/p 3 33/127 (26) 15/105 (14.3) 1.68 (0.67421) 
*Total number of Patients with adverse events on amodiaquine 52/488 (10.7%) due 
to patients enrolled in threearm studies with both chloroquine and S/P. 
Table 3: Adverse events from trials 
a 
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Tolerability 
From the trials that met the inclusion criteria for the 
effectiveness analyses, only 10 reported some evidence of 
tolerability assessment, accounting for 488 amodiaquine, 
411 chloroquine, and 105 SIP patients. Adverse events 
were reported for 52 amodiaquine patients (10.7%), 36 on 
chloroquine (8.8%), and 15 on SIP (14.3%). No 
significant difference was observed between amodiaquine 
and chloroquine or SIP (table 3). The most commonly 
reported adverse events with amodiaquine were 
gastrointestinal (nausea and vomiting) and pruritus. No 
association was found between amodiaquine dose and 
incidence of adverse events. Those reported were of minor 
or moderate severity, and no severe, life-threatening 
adverse drug reaction was reported for amodiaquine. 
A complete biochemical and haematological evaluation 
was performed for the 62 amodiaquine and 59 chloroquine 
patients in a study in Ivory Coast. No difference was 
observed between the two groups. Neutrophil counts on 
thick smear were available for 191 amodiaquine, 22 
chloroquine, and 116 S/P recipients from Kenya (C Nevil€, 
unpublished). Paired observations of neutrophil counts on 
day 14 versus baseline values of Ivory Coast and Kenya 
patients showed no significant change; the indices were 
remarkably similar with the three drugs. 
24 non-comparative or non-randomised studies were 
identified, three of which, accounting for 776 amodiaquine 
recipients, reported 450 mild adverse events in 219 
patients (28%). In one study in Cameroun, liver function 
tests were tested in 50 patients before and after treatment, 
with no significant change. In a recent study comparing 
amodiaquine with atovaquone plus proguanil, pruritus (in 
27/63 patients), insomnia, dizziness, and weakness 
occurred more flequently on amodiaquine, while nausea 
and abdominal pain were more common with atovaquone 
plus proguanil. No significant shift in haematological and 
biochemical indices was detected.lo 
Data from two other possibly overlapping data sources 
were also made available. 115 adverse events were reported 
for 66 patients to the WHO Collaborating Centre for 
International Drug Monitoring during 1970-94 (M 
Pettersson, personal communication). These data are 
transmitted to the WHO Collaborating Centre by national 
drug regulatory authorities. The data are not checked at 
country level and information is often incomplete but this 
remains an  important compilation of routine data. The 
most commonly affected body system was “WJ3Cs and 
RES” (white blood cells and reticuloendothelial system). 
There were 28 reports, including 17 cases of 
agranulocytosis and 7 of granulocytopenia. The other body 
systems affected included liver and biliaIy system (n=21), 
skin and appendages (n=lO), and body as a whole (n=9, 
including two deaths). Agranulocytosis and 
granulocytopenia affected adults of both sexes who had 
been on amodiaquine for an average of 9 weeks (range 
3-360 days). In cases of agranulocytosis, time to onset 
varied from 48 to 98 days in seven of these cases; the other 
10 had no dates filled in. Reasons for amodiaquine 
administration were seldom reported. Drug-event 
relationship were reported as certain in one case, probable 
in 11, possible in 13, unlikely in two, and unknown in 39. 
Of the 66 patients 35 had recovered without sequelae at the 
time of reporting, two died due to adverse reactions, in one 
other death the drug may have been contributory, and 11 
patients had not yet recovered; outcome was not recorded 
in the other 17. 
Between 1985 and 1.99.1 (Parke-Davis data on file), 42 
cases of serious adverse effects were reported during 
amodiaquine prophylaxis. These were 28 cases of 
agranulocytosis (9 died) and 14 of hepatitis (3 died). 
Amodiaquine intake ranged between 200 and 700 mg pes 
week for 3-48 weeks. 
Discussion 
Some of the methodological deficiencies in published and 
unpublished trials have inevitably led to a bias in these 
analyses, Most articles report data only on the patients 
deemed “evaluable” as per the protocol, usually those who 
completed the scheduled study period (7, 14, or 28 days). 
Because no details were given on the “eligible” patients, 
and those where treatment was prematurely discontinued 
or who were withdrawn or lost to follow-up, no  true 
intent-to-treat analysis could be done. Obtaining raw data 
has partly rectified the problem, although a selection bias 
still remains in favour of sensitivity. In contrast, the 
criteria adopted in the analysis of eficacy (ie, the missing 
data counted as failures) will introduce a bias toward 
resistance. In fact, non-attendees were shown to do well in 
an ad-hoc study in Kenya (C Nevill, unpublished). The 
availability of data to reanalyse had led us to identify two 
populations-the ‘cevaluable” patients and those actually 
assessed at each target visit. The denominator did not vary 
substantially though; nor did the level of significance of 
the comparisons in the sets of patients. 
The data are mainly from eastern, central, and western 
Africa, and although representing a wide range of malaria 
epidemiological patterns and resistance patterns, care 
should be taken in applying these results elsewhere. In this 
review, amodiaquine was significantly more effective than 
chloroquine in clearing parasites in all analyses done, with 
a tendency also for a faster clinical recovery as tesred by a 
marginal advantage for fever clearance time. With respect 
to SIP no difference in parasitological outcomes was 
observed within 7 days of study, while SIP showed 
superiority during longer-term follow-up. This finding is 
not unexpected in view of the long-half life of SIP. We do 
not know whether the difference observed is due to 
recrudescent parasites or to reinfections. An improvement 
in symptoms was apparent with amodiaquine, as has been 
reported previously, and this could be ascribed to the anti- 
inflammatorylantipyretic effect of the aminoquinolines. 
Amodiaquine seems to be no more toxic than 
chloroquine or SIP when administered at doses up to 35 
mg/kg total dose over three days for treating adult and 
children with uncomplicated falciparum malaria. Under 
these conditions of use, and within the limitations of the 
sample size, no severe, life-threatening, or fatal adverse 
reaction occurred. 
After oral intake, amodiaquine is rapidly and extensively 
metabolised to an active metabolite, desethylamodiaquine; 
both amodiaquine and desethylamodiaquine are 
chemically unstable in aqueous solution, undergoing 
transformation to a protein-arylating quinone imine.” The 
mechanism of toxicity of amodiaquine seems not to be 
related to direct toxicity of the parent compound or 
metabolites in bone marrow cell precursors,12 but rather to 
the immunogenic properties of the quinone imir~e.’~.’~ It is
still unclear why, with most people exposed having anti- 
drug antibody, so few would have organ-specific toxicity. 
SO far, serious and life-threatening adverse drug 
reactions have been described only durhg  prophylaxis. 
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Based on reported rates, the risk of serious reactions 
associated with the prophylactic use of amodiaquine can 
be estimated a t  1 in every 2100 treatments for 
agranulocytosis, 1 in 15 500 for hepatoxicity, and 1 in 
30 O00 for aplastic anaemia, with a total case fatality rate 
of 1 in 15 650L5 (P A Phillips-Howard, personal 
communication). The risk of fatal adverse reactions to 
amodiaquine is similar to that to SIP. 
Amodiaquine treatment appears to be safer than 
amodiaquine prophylaxis. In the 14 cases of 
agranulocytosis andor hepatitis reported1s2 the mean (SD) 
total dose of amodiaquine was 3.44 (1.2) g over 7-7 (2.3) 
weeks, corresponding to 2-3 times the dose of 1-5 g for a 
60 kg individual. Treatment starts to resemble prophylaxis 
in areas where malaria is hyperendemic, where individuals 
receive several malaria treatments per year. Yet very few 
side-effects of amodiaquine treatment are reported. 
Although this review cannot dispel fear of amodiaquine 
toxicity with repeat treatments (that mimic prophylaxis) 
the slow “antipyretic” action of S/P, as well as its 
decreasing efficacy, appears to encourage multiple dose 
regimens with a similar level of risk. 
This review has collated convincing evidence that 
amodiaquine is superior to chloroquine, and that applies 
to areas with considerable chloroquine resistance. There is 
a role for amodiaquine where chloroquine resistance is 
present although that role may be curtailed by partial 
amodiaquine cross-resistance with chloroquine. The 
comparison with S/P is potentially more important in view 
of the value of low-cost antimalarial drugs and the 
concems around the useful life of sulpha drugs with long 
half-lives now that they are so widely used in sub-Saharan 
Africa. The faster symptomatic recovery with 
amodiaquine would avoid the need to give antipyretics, as 
is usual with SIP. The longer protection induced by SIP 
may also prove more of a hazard long-term since it could 
encourage the selection of resistant parasites. 
This review is the most comprehensive attempt to date 
to identify all published and unpublished trials. Another 
review using a different methodology (A Rietveld and 
I? Trigg, unpublished) also judged that the WHO 
recommendation to stop using amodiaquine in malaria 
control programmes for treatment was more prudent than 
practical, especially since so few affordable alternatives are 
available. When chloroquine, amodiaquine, and SA? are 
no longer effective, the next antimalarial drugs in line cost 
7-60 times as much. (A Rietveld, personal 
communication), placing a full .treatment course out of the 
reach of many patients. The review supports the 
continued use of amodiaquine in the treatment of 
uncomplicated malaria. Partial cross-resistance between 
chloroquine and amodiaquine should be borne in mind, 
however, and bdth monitoring of effectiveness and 
surveillance for evidence of toxicity must be maintained. 
This review was made possible by researchers who kindly provided data 
and made comments, and include B Greenwood and O Müller (The 
Gambia), L Salako (Nigeria), A Shapira (WHO, Vietnam), and B Dubois 
(Parke-Davis, France). Data on amodiaquine adverse events were kindly 
provided by M Petersson (WHO Collaborating Cenue, Sweden). Others 
who have helped with specialist advice include A Rietveld and V Mauei 
(WHO, Switzerland), J Portal (Parke-Davis, France), P Winstanley (UK), 
A O m a n  (Denmark), A Herxheimer (UK). Elements of an unpublished 
WHO study by A Rietveld and P Trigg were also used. This review was 
conducted as an activity of the Cochrane Tropical Diseases Group, 
supported by a grant from the Overseas Development Administration 
(UK), and of the UNDPNorld BanknWO Special Programme for 
Research and Training in Tropical Diseases (TDR). 
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